These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8793587)

  • 21. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias.
    Wiesfeld AC; Crijns HJ; Tobé TJ; Almgren O; Bergstrand RH; Aberg J; Haaksma J; Lie KI
    Am J Cardiol; 1992 Oct; 70(11):990-6. PubMed ID: 1384304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient QT prolongation with torsades de pointes tachycardia after ablation of permanent junctional reciprocating tachycardia.
    Grimm W; Hoffmann J; Menz V; Maisch B
    J Cardiovasc Electrophysiol; 1999 Dec; 10(12):1631-5. PubMed ID: 10636193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terminology of torsades de pointes.
    Tzivoni D; Keren A; Banai S; Stern S
    Cardiovasc Drugs Ther; 1991 Apr; 5(2):505-7. PubMed ID: 1854659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the antiarrhythmic and the proarrhythmic effect of almokalant in anaesthetised rabbits.
    Farkas A; Leprán I; Papp JG
    Eur J Pharmacol; 1998 Apr; 346(2-3):245-53. PubMed ID: 9652366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical aspects of polymorphic ventricular tachycardia].
    Leenhardt A; Coumel P; Slama R
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():23-9. PubMed ID: 1307191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dangerous arrhythmias].
    Gertsch M; Fuhrer J
    Schweiz Med Wochenschr; 1993 May; 123(17):833-43. PubMed ID: 8497770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia?
    Krishnan SC; Galvin J; McGovern B; Garan H; Ruskin JN
    J Cardiovasc Electrophysiol; 1997 Sep; 8(9):1055-61. PubMed ID: 9300303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit.
    Carlsson L; Drews L; Duker G; Schiller-Linhardt G
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1076-80. PubMed ID: 8263767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.
    Morganroth J
    Am J Cardiol; 1993 Aug; 72(6):10B-13B. PubMed ID: 8256748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
    Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
    Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the Ikr-blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study.
    Houltz B; Darpö B; Swedberg K; Blomström P; Brachmann J; Crijns HJ; Jensen SM; Svernhage E; Vallin H; Edvardsson N
    Cardiovasc Drugs Ther; 1999 Jul; 13(4):329-38. PubMed ID: 10516869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
    Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S
    J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperglycemia and subsequent torsades de pointes with marked QT prolongation during refeeding.
    Nakashima T; Kubota T; Takasugi N; Kitagawa Y; Yoshida T; Ushikoshi H; Kawasaki M; Nishigaki K; Ogura S; Minatoguchi S
    Nutrition; 2017 Jan; 33():145-148. PubMed ID: 27544004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of class III antiarrhythmic drug therapy.
    Roden DM
    Am J Cardiol; 1993 Aug; 72(6):44B-49B. PubMed ID: 8256755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.